Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Quince Therapeutics, Inc. (QNCX) had Return on Tangible Equity of 34.33% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.03M |
|
-- |
|
-- |
|
$14.86M |
|
$-14.86M |
|
$-0.12M |
|
$-14.98M |
|
$-14.98M |
|
$-15.03M |
|
$-15.03M |
|
$-15.03M |
|
$-15.03M |
|
$-14.86M |
|
$-15.18M |
|
43.94M |
|
43.94M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$33.83M |
|
$0.45M |
|
$73.26M |
|
$107.09M |
|
$8.36M |
|
$15.27M |
|
$80.15M |
|
$88.51M |
|
$18.58M |
|
$-43.78M |
|
$18.58M |
|
44.09M |
|
| Cash Flow Statement Financials | |
$-9.60M |
|
$10.90M |
|
$0.09M |
|
$6.21M |
|
$7.77M |
|
$1.56M |
|
$1.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.05 |
|
-- |
|
-- |
|
0.45 |
|
0.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-80.89% |
|
|
Return on Tangible Equity |
34.33% |
-14.04% |
|
-44.41% |
|
$0.42 |
|
$-0.22 |
|
$-0.22 |
|